NCT06960395View on ClinicalTrials.gov

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

July 22, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2029

Conditions
Solid Tumor MalignanciesEGFR Positive Solid TumorsEGFR
Interventions
DRUG

VIR-5525

Pharmaceutical Form: Solution for Infusion Route of Administration: Intravenous (IV) infusion

DRUG

Pembrolizumab

Pharmaceutical Form: Solution for Infusion Route of Administration: Intravenous (IV) infusion

Trial Locations (3)

2500

RECRUITING

Wollongong Hospital, Wollongong

4102

NOT_YET_RECRUITING

Princess Alexandra Hospital, Woolloongabba

85258-4566

RECRUITING

Honor Health Research Institute, Scottsdale

All Listed Sponsors
lead

Vir Biotechnology, Inc.

INDUSTRY

NCT06960395 - Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter